阿托伐他汀治疗冠心病合并高脂血症的效果和安全性研究  

Efficacy and safety of atorvastatin on the coronary heart disease combined with hyperlipoidemia

作　　者：刘广交[1] 

机构地区：[1]广东省梅州市人民医院心血管内三科,广东梅州514031

出　　处：《中国当代医药》2015年第13期144-146,149,共4页China Modern Medicine

摘　　要：目的：探究阿托伐他汀治疗冠心病合并高脂血症的效果和安全性。方法选取2012年7月-2013年11月来本院就诊的80例冠心病合并高脂血症患者，随机分成观察组和对照组，每组40例，观察组给予阿托伐他汀治疗，对照组给予辛伐他汀治疗。结果经治疗，观察组总有效率为95.00%，对照组总有效率为72.50%，观察组的总有效率明显高于对照组（P〈0.05）；两组治疗后TC、TG及hs-CRP水平较治疗前下降，观察组较对照组下降更明显（P〈0.05）；治疗后，两组的HDL-C水平较治疗前上升，和治疗前对比，差异无统计学意义（P〉0.05）。治疗过程中两组均出现不同程度的药物不良反应，对照组不良反应发生率为17.50%，观察组不良反应发生率为37.50%，差异有统计学意义（P〈0.05）。结论阿托伐他汀治疗冠心病合并高脂血症疗效显著，值得临床推广。Objective To study the efficacy and safety of atorvastatin in patients with coronary artery heart disease combined with hyperlipidemia. Methods 80 patients with coronary artery heart disease and hyperlipidemia in our hos-pital from July 2012 to November 2013 were selected and randomly divided into control group （simvastatin group） and observation group （atorvastatin group）,40 cases in each group. Results The total effective rate in observation group was 95.00%,higher than 72.50%of control group,with statistical difference（P〈0.05）.After treatment,TC,TG and hs-CRP level were significantly decreased between two groups,which in observation group were significantly lower than that in control group （P〈0.05）.HDL-C level between two groups raised after treatment,however there was no significant difference than before（P〉0.05）.Various of adverse drug reactions during treatment was shown between two groups,adverse reactions oc-curred was 37.50% in control group and 17.50% in observation group,with statistical difference （P〈0.05）. Conclusion The efficacy of atorvastatin on patients with coronary heart disease combined hyperlipidemia is obvious,it is worthy of clinical popularization and application.

关 键 词：阿托伐他汀 冠心病 高脂血症 疗效 

分 类 号：R9[医药卫生—药学]